Pirprofen in postoperative course following cataract extraction: a controlled trial.
In a double-blind, between-patient trial, a new cyclo-oxygenase inhibitor, pirprofen (800 mg/day), was compared with indomethacin (100 mg/day) and placebo in 56 patients undergoing cataract extraction. Treatment started 48 h before operation and continued for eight days. Patients were examined on days 1, 3 and 6 for objective signs of inflammation and pain. Both active drugs proved to have good anti-inflammatory action, clearly superior to placebo. No unwanted effects or modifications in laboratory parameters other than those related to the antiphlogistic effect were reported.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002387:Cataract Extraction; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D007249:Inflammation; D010146:Pain; D010666:Phenylpropionates / Q000627:therapeutic use*; D010919:Placebos
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010666:Phenylpropionates; D010919:Placebos; C008924:pirprofen; D007213:Indomethacin